

Resource Summary Report

Generated by [dkNET](#) on Aug 5, 2026

Mutect2

RRID:SCR_026692

Type: Tool

Proper Citation

Mutect2 (RRID:SCR_026692)

Resource Information

URL: <https://gatk.broadinstitute.org/hc/en-us/articles/360037593851-Mutect2>

Proper Citation: Mutect2 (RRID:SCR_026692)

Description: Software tool to call somatic short mutations via local assembly of haplotypes. Somatic variant caller that uses local assembly and realignment to detect SNVs and indels.

Resource Type: software application, software resource

Defining Citation: [DOI:10.1101/861054](https://doi.org/10.1101/861054)

Keywords: Somatic variant caller, call somatic short mutations, detect SNVs and indels,

Resource Name: Mutect2

Resource ID: SCR_026692

Record Creation Time: 20250401T060330+0000

Record Last Update: 20260805T044602+0000

Ratings and Alerts

No rating or validation information has been found for Mutect2.

No alerts have been found for Mutect2.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1110 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Chow Z, et al. (2026) Colon cancer in Appalachian Kentucky: Unique genetic, microbiome and obesity findings in a cohort comparison. *HGG advances*, 7(1), 100527.

Miglierina E, et al. (2026) DIS3 licenses B cells for plasma cell differentiation in humans. *Cellular & molecular immunology*, 23(1), 31.

Kim CY, et al. (2026) Integrative multi-omics of matched primary and liver metastatic colorectal cancer organoids identifies putative molecular targets. *Translational oncology*, 63, 102592.

Pan R, et al. (2026) Basement membrane-associated gene P3H2 regulates osteosarcoma progression and epithelial-mesenchymal transition through AKT/mTOR signaling axis. *Translational oncology*, 63, 102569.

Liu Y, et al. (2025) SpatialSNV: A novel method for identifying and analyzing spatially resolved SNVs in tumor microenvironments. *GigaScience*, 14.

Mohammadi M, et al. (2025) Cyclin-dependent kinase 9 inhibitors as oncogene signaling modulators in combination with targeted therapy for the treatment of colorectal cancer. *bioRxiv : the preprint server for biology*.

van Ravensteijn SG, et al. (2025) Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(17), 3678.

Kaushik AC, et al. (2025) Integrative machine learning approach for identification of new molecular scaffold and prediction of inhibition responses in cancer cells using multi-omics data. *Briefings in functional genomics*, 24.

Her Y, et al. (2025) Tumor neoantigens as key drivers of significant anti - tumor immunity in triple - negative breast cancer mouse models. *Neoplasia (New York, N.Y.)*, 67, 101205.

Huo ??? X, et al. (2025) Genome-wide Genetic Mutations Accumulated in Pigs Genome-edited for Xenotransplantation and Their Filial Generation. *Genomics, proteomics & bioinformatics*, 23(4).

Mack T, et al. (2025) Germline genetics, disease, and exposure to medication influence longitudinal dynamics of clonal hematopoiesis. *Haematologica*, 110(4), 1010.

Philips S, et al. (2025) Association of heightened host and tumor immunity with prolonged duration of response to checkpoint inhibition across solid tumors. *Scientific reports*, 15(1), 13195.

Kim M, et al. (2025) Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple-negative breast cancer. *Histopathology*, 87(2), 299.

Wu J, et al. (2025) Postoperative metastatic Krukenberg tumors with ARID1A and KRAS mutations in a patient with gastric cancer treated with oxaliplatin and tegafur: A case report. *Oncology letters*, 29(6), 262.

Horisawa Y, et al. (2025) APOBEC3B Does Not Promote Tumor Progression in Tp53 Hemizygous Mice. *Cancer reports (Hoboken, N.J.)*, 8(4), e70189.

Alves JM, et al. (2025) Genomic diversity and BCL9L mutational status in circulating tumor cells predict overall survival in metastatic colorectal cancer. *Cellular oncology (Dordrecht, Netherlands)*, 48(6), 1809.

Huang CY, et al. (2025) Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma. *BMC cancer*, 25(1), 1540.

Artzi SB, et al. (2025) Spatial transcriptomic analysis reveals lack of response to PD-1 blockade in recurrent glioblastoma. *Acta neuropathologica*, 150(1), 29.

Wang JH, et al. (2025) An optimized tissue sampling scheme guided by MRI features reveals intratumoral heterogeneity in glioblastoma. *Scientific reports*, 15(1), 33194.

Zhou J, et al. (2025) The potential role of cuproptosis-related genes for therapy and immunoregulation in pan-cancer. *PloS one*, 20(7), e0324389.